Annual EBITDA
-$196.60 M
-$55.19 M-39.03%
November 30, 2024
Summary
- As of February 8, 2025, NRIX annual EBITDA is -$196.60 million, with the most recent change of -$55.19 million (-39.03%) on November 30, 2024.
- During the last 3 years, NRIX annual EBITDA has fallen by -$84.80 million (-75.84%).
- NRIX annual EBITDA is now -2812.15% below its all-time high of -$6.75 million, reached on November 30, 2018.
Performance
NRIX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$60.35 M
-$9.89 M-19.60%
November 30, 2024
Summary
- As of February 8, 2025, NRIX quarterly EBITDA is -$60.35 million, with the most recent change of -$9.89 million (-19.60%) on November 30, 2024.
- Over the past year, NRIX quarterly EBITDA has dropped by -$19.02 million (-46.03%).
- NRIX quarterly EBITDA is now -2835.51% below its all-time high of -$2.06 million, reached on August 31, 2019.
Performance
NRIX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$196.60 M
-$18.78 M-10.56%
November 30, 2024
Summary
- As of February 8, 2025, NRIX TTM EBITDA is -$196.60 million, with the most recent change of -$18.78 million (-10.56%) on November 30, 2024.
- Over the past year, NRIX TTM EBITDA has dropped by -$53.63 million (-37.51%).
- NRIX TTM EBITDA is now -9462.21% below its all-time high of -$2.06 million, reached on August 31, 2019.
Performance
NRIX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
NRIX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -39.0% | -46.0% | -37.5% |
| 3 y3 years | -75.8% | -51.8% | -14.1% |
| 5 y5 years | -888.8% | -51.8% | -14.1% |
NRIX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -75.8% | at low | -157.6% | at low | -75.8% | at low |
| 5 y | 5-year | -888.8% | at low | -400.4% | at low | -1204.5% | at low |
| alltime | all time | -2812.2% | at low | -2835.5% | at low | -9462.2% | at low |
Nurix Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Nov 2024 | -$196.60 M(+39.0%) | -$60.35 M(+19.6%) | -$196.60 M(+10.6%) |
| Aug 2024 | - | -$50.47 M(+13.5%) | -$177.82 M(+8.4%) |
| May 2024 | - | -$44.45 M(+7.5%) | -$163.99 M(+14.7%) |
| Feb 2024 | - | -$41.33 M(-0.6%) | -$142.97 M(+1.1%) |
| Nov 2023 | -$141.41 M(-18.3%) | -$41.58 M(+13.5%) | -$141.41 M(-2.8%) |
| Aug 2023 | - | -$36.63 M(+56.3%) | -$145.49 M(-4.7%) |
| May 2023 | - | -$23.43 M(-41.1%) | -$152.69 M(-11.4%) |
| Feb 2023 | - | -$39.77 M(-12.9%) | -$172.34 M(-0.4%) |
| Nov 2022 | -$173.06 M | -$45.65 M(+4.2%) | -$173.06 M(+5.7%) |
| Aug 2022 | - | -$43.83 M(+1.7%) | -$163.75 M(+11.2%) |
| May 2022 | - | -$43.08 M(+6.4%) | -$147.31 M(+14.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Feb 2022 | - | -$40.49 M(+11.4%) | -$129.16 M(+15.5%) |
| Nov 2021 | -$111.80 M(+78.0%) | -$36.34 M(+32.7%) | -$111.80 M(+17.9%) |
| Aug 2021 | - | -$27.39 M(+9.8%) | -$94.83 M(+10.2%) |
| May 2021 | - | -$24.93 M(+7.8%) | -$86.08 M(+16.5%) |
| Feb 2021 | - | -$23.14 M(+19.5%) | -$73.88 M(+17.6%) |
| Nov 2020 | -$62.80 M(+215.9%) | -$19.36 M(+3.9%) | -$62.80 M(+11.2%) |
| Aug 2020 | - | -$18.64 M(+46.4%) | -$56.45 M(+41.6%) |
| May 2020 | - | -$12.73 M(+5.6%) | -$39.87 M(+46.9%) |
| Feb 2020 | - | -$12.06 M(-7.3%) | -$27.13 M(+80.0%) |
| Nov 2019 | -$19.88 M(+194.5%) | -$13.02 M(+533.0%) | -$15.07 M(+633.0%) |
| Aug 2019 | - | -$2.06 M | -$2.06 M |
| Nov 2018 | -$6.75 M | - | - |
FAQ
- What is Nurix Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Nurix Therapeutics?
- What is Nurix Therapeutics annual EBITDA year-on-year change?
- What is Nurix Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Nurix Therapeutics?
- What is Nurix Therapeutics quarterly EBITDA year-on-year change?
- What is Nurix Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Nurix Therapeutics?
- What is Nurix Therapeutics TTM EBITDA year-on-year change?
What is Nurix Therapeutics annual EBITDA?
The current annual EBITDA of NRIX is -$196.60 M
What is the all time high annual EBITDA for Nurix Therapeutics?
Nurix Therapeutics all-time high annual EBITDA is -$6.75 M
What is Nurix Therapeutics annual EBITDA year-on-year change?
Over the past year, NRIX annual EBITDA has changed by -$55.19 M (-39.03%)
What is Nurix Therapeutics quarterly EBITDA?
The current quarterly EBITDA of NRIX is -$60.35 M
What is the all time high quarterly EBITDA for Nurix Therapeutics?
Nurix Therapeutics all-time high quarterly EBITDA is -$2.06 M
What is Nurix Therapeutics quarterly EBITDA year-on-year change?
Over the past year, NRIX quarterly EBITDA has changed by -$19.02 M (-46.03%)
What is Nurix Therapeutics TTM EBITDA?
The current TTM EBITDA of NRIX is -$196.60 M
What is the all time high TTM EBITDA for Nurix Therapeutics?
Nurix Therapeutics all-time high TTM EBITDA is -$2.06 M
What is Nurix Therapeutics TTM EBITDA year-on-year change?
Over the past year, NRIX TTM EBITDA has changed by -$53.63 M (-37.51%)